Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
In DMSO RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献137篇:

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 M1TzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy3NkBp MoPkSG1UVw>? M1jTSWlEPTB;MD6wNFAxPyEQvF2= MXmxO|k2PjB6MB?=
K562 M1zBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7JcY93PzJiaB?= NHjRVFVFVVOR NEjUSlRKSzVyPUCuNFAyKM7:TR?= NH2wNIcyPzl3NkC4NC=>
M07e NVLBXWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm3NkBp NU\KcIpxTE2VTx?= MUPJR|UxRTBwMECxNkDPxE1? NV\0e4tZOTd7NU[wPFA>
ALL3 MmjCR5l1d3SxeHnjJGF{e2G7 NEPLfFIxNjIQvF2= MWq3NkBp NHjaOWVFVVOR NWnvV2s6UUN3ME2wMlAxODRizszN NVHQe|E{OTl6OEm1OFA>
CML M4TtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHhbpI3OjBibXnu M37xfmROW09? NYLpZVhOUUN3ME2wMlAxOSEQvF2= Mn;VNVkzOTlyMU[=
BA/F3 M2\JUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDzfphUPzJiaB?= NGX5UodFVVOR NEWzNHBKSzVyPU[uOVg6KM7:TR?= MX:yN|A5QDZ2NB?=
BA/F3 NFe0W3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnWZ4M4OiCq MVnEUXNQ MYrJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= MWKyN|A5QDZ2NB?=
BA/F3 M1izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS3NkBp M{fiVGROW09? NHWyOWhKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP NF\Y[mgzOzB6OE[0OC=>
BA/F3 M2DrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[3NkBp MmTlSG1UVw>? MmDrTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP NEDVbGUzOzB6OE[0OC=>
BA/F3 M4PHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq5PFVzPzJiaB?= M4\5fGROW09? M1;RR2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP M1XHcFI{OzBzN{Cz
BA/F3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj2O|IhcA>? NFPPOFdFVVOR M3PzZWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP NUnGdo5jOjN|MEG3NFM>
BA/F3 M1fi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjCO|IhcA>? Ml;BSG1UVw>? NGLtZo9KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= MlPxNlM{ODF5MEO=
BA/F3 M4DxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXKToUxPzJiaB?= NWH2e5Y6TE2VTx?= M2ftUWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1? NFnye2wzOzNyMUewNy=>
BA/F3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nzVlczKGh? MoLYSG1UVw>? Mm\STY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1? NEDDPZkzOzNyMUewNy=>
BA/F3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[3NkBp M2LjNGROW09? M3rIfGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO NF;Me4czOzNyMUewNy=>
BA/F3 NFXtUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH1WVlOPzJiaB?= M{H6WWROW09? NX2wNJJkUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2= MXOyN|MxOTdyMx?=
BA/F3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK3NkBp MUDEUXNQ MljHTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0> MonINlM{ODF5MEO=
BA/F3 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW0O|IhcA>? M2\Ib2ROW09? M{D3TWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?= NVHVSXNsOjN|MEG3NFM>
T cell NHj5UnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17O[VczKGh? MkjwSG1UVw>? NYTSemFUUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? NGX0RWcyPzF3NEWxNi=>
WiDr NFj0cIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrQT2t3PzJiaB?= MXvEUXNQ M4[1SmlEPTB;MD6wOVIh|ryP NYjvdGlzOTV4MUW1NVI>
PC3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXwO|IhcA>? NX[1Z3B3TE2VTx?= NWTwUHhoUUN3ME2wMlAxQTRizszN Mo\YNVU3OTV3MUK=
MDA-MB-231 M2jDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjGTlZZPzJiaB?= NEPITWxFVVOR MnXMTWM2OD1yLkCxNkDPxE1? NEXTOo4yPTZzNUWxNi=>
Hs578T MkT4R5l1d3SxeHnjJGF{e2G7 NEDF[Jg4OiCq M3L3O2ROW09? Mn3BS2k2OD1yLkCzJO69VQ>? M3rrSlI1ODF3M{K3
HMEC NXvZVXlyS3m2b4TvfIlkKEG|c3H5 MnvWO|IhcA>? Ml\kSG1UVw>? MYrHTVUxRTFwODFOwG0> MUmyOFAyPTN{Nx?=
DU145 MlTuR5l1d3SxeHnjJGF{e2G7 M4D1ZlczKGh? NYDkPItqTE2VTx?= Mm\GS2k2OD1yLkG2JO69VQ>? M2HlPFI1ODF3M{K3
U251 MnntR5l1d3SxeHnjJGF{e2G7 M2qwT|czKGh? Mnz3SG1UVw>? NGPVWlhIUTVyPUKuPFEh|ryP MnvZNlQxOTV|Mke=
NCI60 Mnz3R5l1d3SxeHnjJGF{e2G7 Mn\tO|IhcA>? NXPhbVJHTE2VTx?= NHS4W3hIUTVyPUWuO{DPxE1? NH7ibmQzPDBzNUOyOy=>
MALME-3M NGPaTllEgXSxdH;4bYMhSXO|YYm= M1PZUlczKGh? NWG2VpZ{TE2VTx?= M3L0cGdKPTB;Nj62NUDPxE1? MmjhNlQxOTV|Mke=
KM12 MV3DfZRwfG:6aXOgRZN{[Xl? NFHn[Ig4OiCq M1z2R2ROW09? MUfHTVUxRTdwNESg{txO M{PZZlI1ODF3M{K3
SW620 NXPoUW1{S3m2b4TvfIlkKEG|c3H5 NVryV5M2PzJiaB?= NWjrVXRnTE2VTx?= Mny2S2k2OD16LkSzJO69VQ>? M1:xe|I1ODF3M{K3
RXF 393NL NFfYbolEgXSxdH;4bYMhSXO|YYm= NYDDXGtTPCCmYYnz MonXSG1UVw>? M13nXGlEPTB;MD6wNlE4KM7:TR?= M2TEPFI{OjV|MEe0
LXFA 983L MXLDfZRwfG:6aXOgRZN{[Xl? NYfueWZ[PCCmYYnz MVnEUXNQ M4SzbmlEPTB;MD6wOVY2KM7:TR?= NX3oUG1lOjN{NUOwO|Q>
PRXF DU145 MmT3R5l1d3SxeHnjJGF{e2G7 MlfKOEBl[Xm| MWrEUXNQ NUDG[WZmUUN3ME2wMlA3OjNizszN MWSyN|I2OzB5NB?=
PAXF 1657L NHXKVYNEgXSxdH;4bYMhSXO|YYm= MkjyOEBl[Xm| MlPKSG1UVw>? NXj1dm0yUUN3ME2wMlEzOSEQvF2= NV\SRoRjOjN{NUOwO|Q>
CXF 1103L MXfDfZRwfG:6aXOgRZN{[Xl? MnzDOEBl[Xm| NVTId5AxTE2VTx?= M4jMZWlEPTB;ND6zOkDPxE1? MkS0NlMzPTNyN{S=
GXF251L M3vjcGN6fG:2b4jpZ{BCe3OjeR?= NGDsWXg1KGSjeYO= MUHEUXNQ NX7BcWQxUUN3ME2yMlI2KM7:TR?= NWTEe4xWOjN{NUOwO|Q>
NCI-H23 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n5WlczKGh? NYHmS3FjTE2VTx?= M1LDcmlEPTB;Mj6yO{DPxE1? MoPsNlM2OjFyMkC=
HCT116 NFu4[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSy[IhqPzJiaB?= NGfBS4JFVVOR MY\JR|UxRTJwMzFOwG0> MmHONlM2OjFyMkC=
MCF7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjJNoRLPzJiaB?= NEHaVJhFVVOR M2\y[mlEPTB;Mj61O{DPxE1? NED2UFAzOzV{MUCyNC=>
NCI-H460 M{DTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrMZok4OiCq M1vOdGROW09? NXnzT2JZUUN3ME24Mlk6KM7:TR?= MWGyN|UzOTB{MB?=
DLD1 M1PUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnHXmtCPzJiaB?= NGm5PZdFVVOR MUPJR|UxRTRwNjFOwG0> NHrRNpUzOzV4N{m2NC=>
NCI-H661 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3lO|IhcA>? M3TtZWROW09? MYTJR|UxRTdwODFOwG0> NIPXSFUzOzV4N{m2NC=>
A549 M{f0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fQRlczKGh? MlLXSG1UVw>? M4PQbWlEPTB;OD6yJO69VQ>? MmPZNlM2Pjd7NkC=
U937 NFLQR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYq3NkBp NWn4d5puTE2VTx?= MVjJR|UxRTF{LkKg{txO NYL6O29tOjN3Nke5OlA>
HEK293 M2f1RWZ2dmO2aX;uJGF{e2G7 NXW2N5llOTEEoN88US=> M1jrWGROW09? M17ocGlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN MX2yNlc4ODZzMB?=
HUVEC MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G1S|AvOTYEoN88US=> NGfOWlY4OiCq NVfueYw6TE2VTx?= NWq3RoZMUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO NXS4bHdpOjJ6NUO5PVM>
HUVEC NFHTZ4tHfW6ldHnvckBCe3OjeR?= NEPOO28yPcLizszN MlXkO|IhcA>? NUjWc4tiTE2VTx?= M2TLT2lv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO MoCyNlI5PTN7OUO=
Plasmodium falciparum M4fkbGZ2dmO2aX;uJGF{e2G7 MX:xNOKh|ryP MUOxOUBucW5? NFSzU3NFVVOR MmfYTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO NHnweVIzPDV3MEOzNC=>
PC3 NEezOmpHfW6ldHnvckBCe3OjeR?= MlTBNE4yKM7:TR?= NIi5U3Q2KGh? MUXEUXNQ MWfJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1? NVLWNHNvOTl2NkK5O|U>
DU145 NIPXe4hHfW6ldHnvckBCe3OjeR?= MXmwMlEh|ryP MYO1JIg> M4DKPGROW09? NVjSbohsUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0> MW[xPVQ3Ojl5NR?=
PC3 NXu2b4N7U2mwYYPlJGF{e2G7 MXmwMlEh|ryP NYD1RpZRPSCq NH;qZYdFVVOR M4ezdWlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= MYixPVQ3Ojl5NR?=
DU145 MYjLbY5ie2ViQYPzZZk> M{KwN|AvOSEQvF2= MkG0OUBp MmToSG1UVw>? M{D0WGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> MkjFNVk1PjJ7N{W=
PC3 M1LPU2tqdmG|ZTDBd5NigQ>? MYiwMlEh|ryP MonFOUBp M{PCZmROW09? NECyUXpKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? NVXpOG4yOTl2NkK5O|U>
DU145 NFjqZoVMcW6jc3WgRZN{[Xl? M33acVAvOSEQvF2= NIXmdVE2KGh? NIfjZmRFVVOR NWrBU4p[UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= M3TKXlE6PDZ{OUe1
Huh7 M{f2TWFvfGm4aYLhcEBCe3OjeR?= NFzFSpYzNjVizszN NETuSXQ1KGSjeYO= NWi3VmtxTE2VTx?= M1TNR2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NHfyO5kyPzN4ME[3Oi=>
C6/36 M1HCT2FvfGm4aYLhcEBCe3OjeR?= Mnj4Nk42KM7:TR?= NXfHNFgxPCCmYYnz M3O2SGROW09? NWKxbm5DUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= M4TxNVE4OzZyNke2
U937 MoHJSpVv[3Srb36gRZN{[Xl? MYGxJO69VQ>? MYOxJIg> M1TEcWROW09? NUjPfYVvWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NGnFe2MyPzZ6NEC5PS=>
U937 M3njW2Z2dmO2aX;uJGF{e2G7 MWCxJO69VQ>? M4HESVEhcA>? MmCwSG1UVw>? MkPhVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> MofCNVc3QDRyOUm=
murine mast cell NXzqe|ZGTnWwY4Tpc44hSXO|YYm= M3rHfFEh|ryP M{PQTlI1KGh? NIXJRpVFVVOR MnG5TY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1? M1e5ZlE4Pjh2MEm5
BV-173 NVzSV2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEiwVpJKSzVyPUCuNFAxODByMUC5JO69VQ>? NWX2WJl{W0GQR1XS
K-562 NX3SbWlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK2RmxUUUN3ME2wMlAxODByMEK2OkDPxE1? NWPj[Wx{W0GQR1XS
BL-70 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;PTWp{UUN3ME2wMlAxODByMEiyNkDPxE1? M1GwenNCVkeHUh?=
EM-2 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\nUWlEPTB;MD6wNFAxODFyODFOwG0> M3e3eHNCVkeHUh?=
LAMA-84 NGXrcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMECwNFA{OjFizszN MkHqV2FPT0WU
MEG-01 M4jRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCdnlmUUN3ME2wMlAxODByOUig{txO NXXqXHp1W0GQR1XS
EoL-1-cell MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMECwNFE{OSEQvF2= NVj1T5NsW0GQR1XS
CTV-1 NWq2NVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\LTWM2OD1yLkCwNFA1ODRizszN M{\JW3NCVkeHUh?=
TE-15 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEC1PFkh|ryP MnrJV2FPT0WU
NOS-1 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnpWVY3UUN3ME2wMlAxPjF|IN88US=> NGjXZ5ZUSU6JRWK=
D-336MG MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7KTWM2OD1yLkCwOlMh|ryP MofIV2FPT0WU
LB1047-RCC NHW3TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\1TWM2OD1yLkCwPVg6KM7:TR?= MlTRV2FPT0WU
LB996-RCC NXzQc3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPITWM2OD1yLkCwPVkyKM7:TR?= NX7jSIxSW0GQR1XS
SW982 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nJXGlEPTB;MD6wNVEyPSEQvF2= MofSV2FPT0WU
TK10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S5OGlEPTB;MD6wNVE4PCEQvF2= MnvMV2FPT0WU
A704 M{TEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hle2lEPTB;MD6wNVQ6OSEQvF2= MWDTRW5ITVJ?
TE-8 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\rWJc1UUN3ME2wMlAyPTd4IN88US=> MXjTRW5ITVJ?
DOHH-2 NHLxW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLVR5ZEUUN3ME2wMlAyPzF7IN88US=> NU\TbW5iW0GQR1XS
HOP-62 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULLVGxiUUN3ME2wMlAyQDN2IN88US=> NUnyR21MW0GQR1XS
TE-12 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O2c2lEPTB;MD6wNVg3OSEQvF2= NUizZYV2W0GQR1XS
KGN NF:xcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLpTGlKSzVyPUCuNFE6PDJizszN M{fiZXNCVkeHUh?=
NCI-H1648 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorXTWM2OD1yLkCyNFEyKM7:TR?= NYm1XmZ3W0GQR1XS
OS-RC-2 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEKwN{DPxE1? M{jkTHNCVkeHUh?=
GB-1 NXfEdHNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq1OpNvUUN3ME2wMlAzOTV5IN88US=> M3LFe3NCVkeHUh?=
RXF393 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEKzOVch|ryP MX\TRW5ITVJ?
LC-2-ad NYC3dYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEK1PFYh|ryP NWDTUYlXW0GQR1XS
KS-1 M1;qOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jRVWlEPTB;MD6wNlc{KM7:TR?= NFznTYpUSU6JRWK=
ETK-1 NWP2NZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEK4N|Ih|ryP MkK2V2FPT0WU
SW954 M4rzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEK5Nlch|ryP NHjnTGpUSU6JRWK=
Becker NXvldpA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjq[Vd2UUN3ME2wMlA{ODB|IN88US=> M1vpUnNCVkeHUh?=
MZ1-PC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvqZ|dmUUN3ME2wMlA{OTF7IN88US=> M2\wSXNCVkeHUh?=
ES6 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Hdo1KSzVyPUCuNFMyQTNizszN M3W0[3NCVkeHUh?=
KURAMOCHI MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr4T2lKSzVyPUCuNFM1QDdizszN Mne4V2FPT0WU
CGTH-W-1 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMEO1OFgh|ryP MlniV2FPT0WU
VA-ES-BJ NHzER5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEO5NFIh|ryP Mn7nV2FPT0WU
LXF-289 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHtTWM2OD1yLkCzPVU3KM7:TR?= MnzPV2FPT0WU
MPP-89 M1O3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofKTWM2OD1yLkC0NFQ6KM7:TR?= NWXNSVVLW0GQR1XS
SW872 NEi3b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;MR|NKSzVyPUCuNFQyPjFizszN M{PJW3NCVkeHUh?=
SNB75 NISyd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT3TWM2OD1yLkC0OFM2KM7:TR?= NV\EUFVZW0GQR1XS
PSN1 Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e4VmlEPTB;MD6wOFQ4PCEQvF2= NUPiUIZ5W0GQR1XS
LB831-BLC NVTZTotsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDOTWM2OD1yLkC0OlA6KM7:TR?= MnHRV2FPT0WU
MFH-ino M2jEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\3[4hKSzVyPUCuNFQ4OjRizszN M{P2fXNCVkeHUh?=
TGBC24TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMES3OlEh|ryP MVHTRW5ITVJ?
A388 NVv6V5VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jH[mlEPTB;MD6wOVA6PSEQvF2= M2\ORnNCVkeHUh?=
BB30-HNC MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEW0N|ch|ryP M4D2dnNCVkeHUh?=
GI-ME-N NIPEOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fVeWlEPTB;MD6wOlEyQCEQvF2= M{\rRnNCVkeHUh?=
TGBC1TKB NHzvRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m3SGlEPTB;MD6wOlE3PCEQvF2= MmjXV2FPT0WU
TE-10 NYj6fWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4SxXmlEPTB;MD6wOlM2PyEQvF2= NH71W4ZUSU6JRWK=
A498 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEeyPFQh|ryP M1z6OXNCVkeHUh?=
TE-11 M1\3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3IbWJ6UUN3ME2wMlA4QDV6IN88US=> NFTaO3NUSU6JRWK=
BB65-RCC NIDyTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPnTWM2OD1yLkC4NlI4KM7:TR?= NXzYSoE6W0GQR1XS
C2BBe1 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITBT2RKSzVyPUCuNFg{ODhizszN M3nIWXNCVkeHUh?=
NCI-H747 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHNOIJPUUN3ME2wMlA5OzZ{IN88US=> NHP2bJNUSU6JRWK=
IST-MES1 M3fOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr4OHFKSzVyPUCuNFg2PTJizszN NX\ydXFyW0GQR1XS
KALS-1 NXvseYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLZTWM2OD1yLkC5OFkh|ryP M4H1e3NCVkeHUh?=
GCIY Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEm2OVYh|ryP MXHTRW5ITVJ?
RL95-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMUCzPEDPxE1? NHfQ[VZUSU6JRWK=
TE-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\TN2lEPTB;MD6xNFU1KM7:TR?= NUPiVlZRW0GQR1XS
NCI-H1355 NHHCNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfWepNNUUN3ME2wMlEyODJ6IN88US=> NFrVNYpUSU6JRWK=
SW962 NXPac4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OwUGlEPTB;MD6xNVI6OiEQvF2= NH\jNGFUSU6JRWK=
KLE NFTFbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSzdFhDUUN3ME2wMlEyOzF5IN88US=> MV\TRW5ITVJ?
MC116 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMUG0NUDPxE1? NInhUoNUSU6JRWK=
NMC-G1 NIPEVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMUG2NFYh|ryP NFTzcG5USU6JRWK=
KU812 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki2TWM2OD1yLkGxPFg{KM7:TR?= NFzBfWdUSU6JRWK=
COLO-829 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULGfWl6UUN3ME2wMlEzOjF|IN88US=> NXj5V5pLW0GQR1XS
NTERA-S-cl-D1 NIPwRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHoTWM2OD1yLkGyNlg{KM7:TR?= MV;TRW5ITVJ?
IST-MEL1 NWi3e2dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW4[pNpUUN3ME2wMlE{PDVizszN MXTTRW5ITVJ?
MLMA M4\GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO1OlBKSzVyPUCuNVQxOzJizszN MXTTRW5ITVJ?
LS-123 NUP1Z|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXKdWtPUUN3ME2wMlE1ODZ2IN88US=> NIL1V|VUSU6JRWK=
LB2518-MEL M{faOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\5bYhFUUN3ME2wMlE1OTZ{IN88US=> NIDoeFFUSU6JRWK=
NB69 Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXvTWM2OD1yLkG0OFM3KM7:TR?= M1e5VXNCVkeHUh?=
8-MG-BA MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMUW0OVgh|ryP MkPpV2FPT0WU
K5 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KfpRVUUN3ME2wMlE3PDh7IN88US=> M2PTUHNCVkeHUh?=
KINGS-1 NYriT5BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvVTWM2OD1yLkG2OlY3KM7:TR?= M1Pm[XNCVkeHUh?=
SF268 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrPU5RTUUN3ME2wMlE4PDB2IN88US=> MVzTRW5ITVJ?
PF-382 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f5TWlEPTB;MD6xO|Y4QCEQvF2= NXfyOXdCW0GQR1XS
SH-4 NH;FdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTBTWM2OD1yLkG4OFE{KM7:TR?= NIDmcnpUSU6JRWK=
NALM-6 NFXoUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zNN2lEPTB;MD6xPVI6PSEQvF2= MnW5V2FPT0WU
CP66-MEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPzPZlKSzVyPUCuNVk2OzFizszN NWK0OFBwW0GQR1XS
697 NUXR[FFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrXTWM2OD1yLkG5PVg4KM7:TR?= NWflOGo{W0GQR1XS
CP67-MEL MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm0PXhKSzVyPUCuNlA1QDhizszN M2f4R3NCVkeHUh?=
DSH1 NInYXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMkSwNFEh|ryP NWDmUVN7W0GQR1XS
HCE-4 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV33emZmUUN3ME2wMlI3PDN7IN88US=> NELuSVhUSU6JRWK=
MZ2-MEL M4\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW4[G9KSzVyPUCuNlg2OzdizszN M3S1V3NCVkeHUh?=
BL-41 NVfXS4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXpTWM2OD1yLkK5NVI{KM7:TR?= M4DXS3NCVkeHUh?=
HUTU-80 M{nHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjr[m1KSzVyPUCuN|E1OiEQvF2= NVHNNpV4W0GQR1XS
LOXIMVI M3fKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPvdY5MUUN3ME2wMlMyPTB|IN88US=> MULTRW5ITVJ?
no-10 NGrXWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkexTWM2OD1yLkOxPVMyKM7:TR?= NY\UeFJoW0GQR1XS
KARPAS-422 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwM{O5PVch|ryP MUDTRW5ITVJ?
SW684 NX\lPIVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfQbHZkUUN3ME2wMlM1QThizszN M3:2ZnNCVkeHUh?=
SF126 NV\5[HFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LncmlEPTB;MD6zOVQyKM7:TR?= MmLaV2FPT0WU
D-263MG M{e4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLuTWM2OD1yLkO2NlI1KM7:TR?= NUfhT3FkW0GQR1XS
OVCAR-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nQNmlEPTB;MD6zO|Q{OyEQvF2= MoT3V2FPT0WU
BB49-HNC NWOzbJJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPsVmtbUUN3ME2wMlM5PTl7IN88US=> MWXTRW5ITVJ?
ONS-76 M4fjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHYTWM2OD1yLkSyPVUyKM7:TR?= NYLXcIFjW0GQR1XS
MZ7-mel MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXUV3RuUUN3ME2wMlQ4QTFzIN88US=> MYrTRW5ITVJ?
RCC10RGB Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O5TmlEPTB;MD60PVEyKM7:TR?= MXzTRW5ITVJ?
BOKU MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLJVVdKSzVyPUCuOFkyOzNizszN NYjzO5NyW0GQR1XS
no-11 NGK3ZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrXTWM2OD1yLkWwNlI5KM7:TR?= M1PTfnNCVkeHUh?=
IST-SL2 NWP1WIltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTETWM2OD1yLkWwN|AzKM7:TR?= M1GxXXNCVkeHUh?=
RKO MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX5TWM2OD1yLkWyPVY3KM7:TR?= NWnGToJnW0GQR1XS
HT-144 NF3VcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjkNZhKSzVyPUCuOVM3ODlizszN Mki0V2FPT0WU
NCI-H446 NX3OfGJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rEUGlEPTB;MD62Nlc3KM7:TR?= NEnNVWJUSU6JRWK=
QIMR-WIL NUnRdplFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WweGlEPTB;MD63NFYzQSEQvF2= NWjtfVJGW0GQR1XS
MHH-PREB-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37PUGlEPTB;MD63OFQ3QSEQvF2= M4\KSnNCVkeHUh?=
EW-16 NHrzdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwN{[xO|gh|ryP Mnf0V2FPT0WU
EW-24 M{O2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\PZpJKSzVyPUCuO|gyPjVizszN NGjQUYRUSU6JRWK=
LB373-MEL-D NYXEWZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\aTGtKSzVyPUCuPFI2ODhizszN MmLGV2FPT0WU
TE-9 NGrmdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLMTWM2OD1yLki3OVMzKM7:TR?= NUnTPYJpW0GQR1XS
A3-KAW M2H6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTNTXNVUUN3ME2wMlk5PDV{IN88US=> NWPvOpZvW0GQR1XS
A101D Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3NTWM2OD1zLkCzNFQ{KM7:TR?= Ml\IV2FPT0WU
OCUB-M M4fORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELCS3FKSzVyPUGuNFQ1OTJizszN MlTIV2FPT0WU
ES4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLyNW9KSzVyPUGuNFUyPDVizszN NHTDUXRUSU6JRWK=
TE-6 NHXJV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jH[GlEPTB;MT6yNVIzPiEQvF2= MUHTRW5ITVJ?
D-502MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwMkOzO|Yh|ryP NWL6WpZEW0GQR1XS
KNS-42 NXTvdlNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\iV4hKSzVyPUGuNlQ1OTJizszN NH\x[nhUSU6JRWK=
SNU-C2B MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwM{C1PFkh|ryP MorBV2FPT0WU
NCI-H1838 M1PPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TCTWlEPTB;MT6zNFc{OyEQvF2= M2LFPXNCVkeHUh?=
NKM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XWVmlEPTB;MT6zNFg2QSEQvF2= MVHTRW5ITVJ?
GI-1 NYi4fGVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwM{[yNkDPxE1? MkTiV2FPT0WU
NB5 NHvWWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7pZ4VKSzVyPUGuN|k5OjdizszN NGXGc4tUSU6JRWK=
CAS-1 NXric2pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XJS2lEPTB;MT60NFk6OiEQvF2= NEDPdWhUSU6JRWK=
HCE-T NInqbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLve|JXUUN3ME2xMlU3PzF2IN88US=> MkLFV2FPT0WU
SBC-1 NVz1UoRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Ti[mlEPTB;MT61O|k5PCEQvF2= M{[0enNCVkeHUh?=
JiyoyeP-2003 NHOyNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHSN|NuUUN3ME2xMlc{PDZ4IN88US=> MYfTRW5ITVJ?
TE-5 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjuWIxqUUN3ME2xMlc6OTN7IN88US=> NV7xOFBzW0GQR1XS
CAN MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwOEKyOVIh|ryP NYS1dW5ZW0GQR1XS
SK-UT-1 NFvi[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTFOYx4UUN3ME2yMlE3Pjl|IN88US=> M2P1UHNCVkeHUh?=
JVM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO1eFRKSzVyPUKuN|YzQDRizszN NGK4fXdUSU6JRWK=
LB771-HNC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnpV|l2UUN3ME2yMlU4PTVzIN88US=> NWL0OYVuW0GQR1XS
NCCIT MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPMXItmUUN3ME2yMlg3PjF4IN88US=> Mnq5V2FPT0WU
NCI-H2126 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3DPI51UUN3ME2yMlg4PTV{IN88US=> Mk\TV2FPT0WU
Calu-6 M{TrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X3U2lEPTB;Mz6wOVc1OSEQvF2= MU\TRW5ITVJ?
SK-LMS-1 NEnZRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWyTWM2OD1|LkGxPFg3KM7:TR?= MYfTRW5ITVJ?
ARH-77 M{HpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHwTWM2OD1|LkS2PVE2KM7:TR?= MX\TRW5ITVJ?
NB17 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DqcGlEPTB;Mz62N|g1PyEQvF2= NVLNWXdWW0GQR1XS
A253 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\JbmpWUUN3ME2zMlc{OjR4IN88US=> Moj5V2FPT0WU
OPM-2 M3jNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPOTphHUUN3ME20MlI4Pjh3IN88US=> M4XCR3NCVkeHUh?=
MV-4-11 M3ToSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj5O5g5UUN3ME20MlM3PDV2IN88US=> MULTRW5ITVJ?
SR M1LRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;selZKSzVyPUSuOFk6PTRizszN M1XmSXNCVkeHUh?=
KG-1 NWi1NpFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LiVmlEPTB;ND62NFg1PSEQvF2= MV;TRW5ITVJ?
OCI-AML2 NI\NfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLETWM2OD13Lki2NVU1KM7:TR?= M3PBb3NCVkeHUh?=
D-247MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTZwMUK1NVkh|ryP NY\ufolGW0GQR1XS
DJM-1 M2jqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Tx[2lEPTB;Nj60PFU2QCEQvF2= NF;KS5JUSU6JRWK=
RPMI-6666 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q3SmlEPTB;Nz6yO|A3PyEQvF2= NU\XcoF3W0GQR1XS
KARPAS-45 NVTmb|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnnbYZTUUN3ME23MlUyPjdzIN88US=> NIPhNoRUSU6JRWK=
LP-1 NHj2VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL6TXRKSzVyPUeuOVQ4QDJizszN M3jwfnNCVkeHUh?=
RS4-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jofGlEPTB;Nz62OVc5PyEQvF2= NG[0TGlUSU6JRWK=
DU-4475 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRThwMkG2OVIh|ryP M3nVOHNCVkeHUh?=
MONO-MAC-6 NHzHWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkizTWM2OD16LkK3NFY3KM7:TR?= MoD3V2FPT0WU
NCI-SNU-16 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFyyPZRKSzVyPUiuOVYyOjhizszN MXnTRW5ITVJ?
SJSA-1 M4j1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq3TWM2OD16LkeyPFA2KM7:TR?= NWLCfYtFW0GQR1XS
MMAC-SF NFfyZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRThwN{mzNFch|ryP MVPTRW5ITVJ?
SK-NEP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\SXG9KSzVyPUiuPFkyPTVizszN NVzyWG1WW0GQR1XS
J-RT3-T3-5 NGPvXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rHdWlEPTB;OD65OlUzQSEQvF2= NGHrT2RUSU6JRWK=
SKM-1 NYfV[oZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLOV3hDUUN3ME25MlAyPzN2IN88US=> MV;TRW5ITVJ?
LB2241-RCC NIrVSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj3R4RsUUN3ME25MlAzODF{IN88US=> Ml;iV2FPT0WU
SIG-M5 NXO4OmZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT3W4VKSzVyPUmuNFI1QTNizszN MnPLV2FPT0WU
EVSA-T MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPsOot6UUN3ME25MlI4Pzl|IN88US=> NUjjR3hlW0GQR1XS
GT3TKB Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rmRWlEPTB;OT6zOVU1PiEQvF2= NWL3fpRGW0GQR1XS
NB6 M2DpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrqZ3ZKSzVyPUmuPVIzPTlizszN M3fIN3NCVkeHUh?=
EHEB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Ho[WlEPTB;MUCuNFY2PiEQvF2= MXfTRW5ITVJ?
HEL M2PaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFyLkS3O|Yh|ryP MVjTRW5ITVJ?
ALL-PO MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFyLke5N|gh|ryP NHjZPGlUSU6JRWK=
TGW NHLsdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFzLkK4Nlgh|ryP NGrBWpZUSU6JRWK=
BC-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPNTWM2OD1zMj6xNVM5KM7:TR?= NH7lbZRUSU6JRWK=
IA-LM MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF{LkS0OFUh|ryP NXTl[IxUW0GQR1XS
UACC-257 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrjSZZKSzVyPUGyMlkyQThizszN NIn3NJJUSU6JRWK=
KP-N-YS NU\1cox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF{LkmyPFMh|ryP NYLFNHNWW0GQR1XS
Raji MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLrTWM2OD1zMz63OFk4KM7:TR?= M{\BSHNCVkeHUh?=
SF539 NIruVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF|Lki1OVch|ryP NVvZNWF7W0GQR1XS
DMS-153 M1\YTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzBTWM2OD1zND6wNFI5KM7:TR?= MY\TRW5ITVJ?
L-540 NGT4W41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELRV25KSzVyPUG1MlA3PzJizszN MWHTRW5ITVJ?
MN-60 M13Uemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3pWoVHUUN3ME2xOU4yQTd7IN88US=> MV3TRW5ITVJ?
RPMI-8866 NHjRO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:2ZVJKSzVyPUG3MlQ1PTRizszN NGPwcYJUSU6JRWK=
NCI-H510A NX\wToNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXLenBpUUN3ME2xPU4{QTd|IN88US=> NXrQS|NIW0GQR1XS
NB13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDSTWM2OD1zOT60PFc4KM7:TR?= NWrhepZ[W0GQR1XS
HAL-01 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfXTWM2OD1zOT63OVQ{KM7:TR?= NWHiO5hUW0GQR1XS
NCI-H720 M3mxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrUT4w{UUN3ME2yNE4zPzN|IN88US=> MXXTRW5ITVJ?
REH MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJyLk[zOVch|ryP NITUV2dUSU6JRWK=
KNS-81-FD MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvMTWM2OD1{Mz6xOFYh|ryP MoXBV2FPT0WU
HC-1 NUHwN3p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILXclhKSzVyPUK0MlU2PTFizszN MULTRW5ITVJ?
NCI-H2141 NES2dHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPDTWM2OD1{ND63O|U1KM7:TR?= NGTib2NUSU6JRWK=
MOLT-4 NUjw[otOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D1RWlEPTB;Mk[uOlc2OyEQvF2= MYDTRW5ITVJ?
OMC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX6eI5KSzVyPUK3MlE1OjJizszN MmCyV2FPT0WU
LC-1F NFnaTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\x[XZIUUN3ME2yO{4{OjR3IN88US=> M3PSNXNCVkeHUh?=
NCI-H1304 MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ6LkG2Nlgh|ryP NYLvN2dIW0GQR1XS
BC-1 M2TZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;NTWM2OD1{OD62OVEh|ryP NWXIT25CW0GQR1XS
NCI-H64 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ7Lk[yOVMh|ryP M3[wRnNCVkeHUh?=
MOLT-16 M4PpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLH[4c4UUN3ME2yPU43Ojl{IN88US=> NH\mfldUSU6JRWK=
U-87-MG NWmwdlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\PTmlEPTB;M{CuO|Y3KM7:TR?= NIDFRmNUSU6JRWK=
GAK Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorYTWM2OD1|MT6yOlg3KM7:TR?= NInXXo5USU6JRWK=
ES8 NF\UVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjSUHJDUUN3ME2zNk4yOjV{IN88US=> NVSxRpRiW0GQR1XS
HCC1599 NHP4c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN{LkOzNlUh|ryP NH[2SppUSU6JRWK=
EB-3 Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDGSFhvUUN3ME2zOE4{OTF5IN88US=> M3nUTnNCVkeHUh?=
HCC1187 NVTGRZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTN3LkiwOVIh|ryP M4\lOHNCVkeHUh?=
SK-PN-DW MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXuOXQ5UUN3ME2zOk4yQTR|IN88US=> NEmyPIFUSU6JRWK=
JVM-3 NEXrV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN5LkKzN|gh|ryP M1PWVXNCVkeHUh?=
HCC2157 NH;kVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HkdmlEPTB;M{euPVk1PiEQvF2= M3z1fXNCVkeHUh?=
A4-Fuk NEf5flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN6LkGwNFkh|ryP MYjTRW5ITVJ?
COR-L279 NGHpdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfz[YpLUUN3ME20NE4zQDVzIN88US=> M2jnfnNCVkeHUh?=
DEL NF\kNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRzLkmwPFYh|ryP NGH6S2JUSU6JRWK=
NCI-H1395 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXhTWM2OD12Mj6wNVY{KM7:TR?= M2LkR3NCVkeHUh?=
MHH-NB-11 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PY[GlEPTB;NEOuNFgyQCEQvF2= M4\W[HNCVkeHUh?=
NCI-H2107 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSyTpBKSzVyPUSzMlQ5PDZizszN NUHSPYM3W0GQR1XS
NEC8 NIT4bnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP1TWM2OD12ND6zN|Yh|ryP MUTTRW5ITVJ?
COLO-684 NYX1SpN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXrTWM2OD12Nj6yNlU5KM7:TR?= NVHnPGJuW0GQR1XS
LS-411N NHvCbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fGNmlEPTB;NEiuOFc1QCEQvF2= M1mzPXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
+ 展开
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
储存条件 powder
in solvent
别名 BMS-354825

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Not yet recruiting Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic December 2019 Phase 1|Phase 2
NCT04115059 Not yet recruiting Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 2019 Phase 1
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2
NCT03193281 Recruiting Chronic Myeloid Leukemia University of Auckland New Zealand|Leukaemia & Blood Cancer New Zealand July 17 2017 Phase 2
NCT03041701 Recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID